© PR Newswire
13.12.2025
SOBI
LISTED
STO
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
News Preview
Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectorySTOCKHOLM, Dec. 13, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2025
SRRK
LISTED
NASDAQ
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggr...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2025
MLTX
LISTED
NASDAQ
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired MoonLake Immunotherapeutics ("MoonLake" or the Company") (NASDAQ: MLTX) securities between March 10, 2024 and September 29, 2025, inc...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
13.12.2025
JNJ
LISTED
NYSE
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
News Preview
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC HORSHAM, Pa., Dec. 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) a...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
13.12.2025
NGEN
LISTED
TSX
NervGen Pharma Announces Proposed Amendment to Warrants
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Compa...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.12.2025
MIST
LISTED
NASDAQ
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
News Preview
MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal suprave...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2025
BAX
LISTED
NYSE
Deadline Soon: Baxter International, Inc. (BAX) Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX) securities between February 23, 2022 and October 29, 2025, inclusi...
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2025
MYTC
LISTED
CSE
MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement
News Preview
Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the ninth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering")....
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2025
INM
LISTED
NASDAQ
InMed Provides Update on BayMedica Commercial Business
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement. Recently, H.R. 5371, the...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
GENN
LISTED
OTC
Genesis Healthcare Remains Committed to Securing Longterm Stability
News Preview
Genesis Healthcare reiterates dedication to a financial restructuring process centered around current and future patients, residents and staff....
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2025
TLT
LISTED
TSX
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
News Preview
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commen...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
INVA
LISTED
NASDAQ
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
News Preview
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.12.2025
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
News Preview
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 share...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
PRTA
LISTED
NASDAQ
Prothena Announces Board of Directors Update
News Preview
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena’s Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. C...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
EXE
LISTED
TSX
Extendicare Announces December 2025 Dividend of C$0.042 per Share
News Preview
MARKHAM, Ontario, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of December 2025, which is payable on January 15, 2026 to shareholders of record at the close of business on December 31, 2025. Thi...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
UNH
LISTED
NYSE
UnitedHealth Group Announces Earnings Release Date
News Preview
UnitedHealth Group (NYSE: UNH) will release its full year 2025 financial results and provide 2026 financial guidance on Tuesday, January 27, 2026, before the market opens, and will host a teleconference at 8:00 a.m. ET with analysts and investors. This call will be webcast on the Investor Relations page of the company’s website (www.unitedhealthgr...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
ZVRA
LISTED
NASDAQ
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company’s common stock (the “In...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
TEVA
LISTED
TLV
Teva Releases Q4 2025 Aide Memoire
News Preview
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
TEVA
LISTED
TLV
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
News Preview
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day,...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
ALEC
LISTED
NASDAQ
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO an...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on December 9, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
TELA
LISTED
NASDAQ
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units c...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
CAMP
LISTED
NASDAQ
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
AVXL
LISTED
NASDAQ
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
News Preview
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ITGR
LISTED
NYSE
Integer Holdings Corporation (ITGR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INTEGER (ITGR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ANTM
LISTED
NYSE
Elevance Health Reflects On The Changed Role of Health Plans
News Preview
As 2025 draws to a close, Elevance Health highlights how today’s health plans are evolving to better support their members in a broader range of situations that affect health, including cancer diagnoses, mental health crises, and unexpected health concerns during pregnancy. From employer-sponsored health insurance to government-sponsored programs,...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ITGR
LISTED
NYSE
Securities Fraud Investigation Into Integer Holdings Corporation (ITGR) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON INTEGER (ITGR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO R...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
TWST
LISTED
NASDAQ
Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders.
If you currently own Twist stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to t...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release
12 December 2025
WORLDWIDE HEALTHCARE TRUST PLC
(the "Company")
MARKET PURCHA...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
DXCM
LISTED
NASDAQ
DexCom, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
PFE
LISTED
NYSE
Pfizer Declares First-Quarter 2026 Dividend
News Preview
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by P...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
LLY
LISTED
NYSE
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
News Preview
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated diseaseIn all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and extended time to chemotherapy by more than a yearThese dat...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ANTM
LISTED
NYSE
AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries
News Preview
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a+” (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) [NYSE: ELV], as well as most of its non-Blue-branded subsidiaries. In...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.12.2025
ASBP
LISTED
NASDAQ
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
News Preview
ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, received notice (the "Notice") on December 11, 2025, from the Nasdaq Listing Qualifications Panel (the "Hearings Pane...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
IMRX
LISTED
NASDAQ
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system to attack pancreatic tumors by blocking sugar-coated disguises cancer cells use to evade detection[1]. Researchers also engineered an off-the-shelf im...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
IMRX
LISTED
NASDAQ
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /CNW/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system to attack pancreatic tumors by blocking sugar-coated disguises cancer cells use to evade detection[1]. Researchers also engineered an off-the-shelf immunothe...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.12.2025
VSEE
LISTED
NASDAQ
VSee Health, Inc. Announces Postponement of Annual Meeting of Stockholders Until December 30, 2025
News Preview
SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (NASDAQ:VSEE) a leader in innovative telemedicine solutions, today announced that it anticipates that it will not have a sufficient number of shares of the Company's common stock present in person or represented by proxy at the 2025 Annual Meeting of Stockholders (the &q...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
ABT
LISTED
NYSE
Abbott increases quarterly dividend for 54th consecutive year
News Preview
Quarterly dividend increased by 6.8%Quarterly dividend payout has increased more than 70% since 2020408th consecutive quarterly dividend to be paid by Abbott since 1924ABBOTT PARK, Ill., Dec. 12, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
ABSI
LISTED
NASDAQ
AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave
News Preview
Issued on behalf of Aleen Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular behavior before researchers invest months in testing, marking a fundamental shift from traditional trial-and-error ap...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
ABSI
LISTED
NASDAQ
AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave
News Preview
Issued on behalf of Aleen Inc.VANCOUVER, BC, Dec. 12, 2025 /CNW/ -- Equity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular behavior before researchers invest months in testing, marking a fundamental shift from traditional trial-and-error approache...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
MLYS
LISTED
NASDAQ
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
News Preview
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors –...
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2025
MDS.UN
LISTED
TSX
Healthcare Special Opportunities Fund Announces December 2025 Quarterly Distribution
News Preview
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (TSX: MDS.UN) (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.06136 per Class A unit and US$0.05468 per Class U unit. The distribution will be paid on or before Dece...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
ABT
LISTED
NYSE
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organi...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
ABT
LISTED
NYSE
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
News Preview
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Dec. 12, 2025 /CNW/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cance
News Preview
- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 therapy trastuzumab- The Actinium-225 alpha-emitter payload of ATNM-400 induced irreversible double-strand DNA breaks and has the potential...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
MRK
LISTED
NYSE
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treat...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
STAA
LISTED
NASDAQ
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
News Preview
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, has reaffirmed its recommendation that shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) should vote “AGAINST” the proposed acquisition of STAA...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
INCY
LISTED
NASDAQ
Incyte Announces Change to its Board of Directors
News Preview
Incyte (Nasdaq:INCY) today announced the resignation of Hervé Hoppenot from the Company’s Board of Directors, effective immediately. As previously announced, Mr. Hoppenot had been serving as an advisor to the Chief Executive Officer (CEO) and as a member of the Board during a planned transition period.
Mr. Hoppenot joined Incyte in 2014 and previ...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
RCUS
LISTED
NYSE
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
News Preview
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc....
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
THAR
LISTED
NASDAQ
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
News Preview
Tharimmune, Inc. (NASDAQ: THAR) (“Tharimmune” or the “Company”), the first publicly traded company to leverage Canton Coin (“CC”) to support the Canton Network’s ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
SOBI
LISTED
STO
Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
News Preview
Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-MPGN treatment for patients 12 and olderSTOCKHOLM, Dec. 12, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Me...
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
DB
LISTED
TSX
Decibel Announces Results of Annual and Special Meeting of Shareholders
News Preview
CALGARY, AB, Dec. 12, 2025 /CNW/ - Decibel Cannabis Company Inc. (the "Company" or "Decibel") (TSXV: DB) (OTCQB: DBCCF), a market leader in premium cannabis and extract manufactured products, is pleased to announce that the results of its annual and special meeting of shareholders held on December 11, 2025 (the "Meeting")....
Themefolio
Profiler
Peergroup
© PR Newswire
12.12.2025
DB
LISTED
TSX
Decibel Announces Results of Annual and Special Meeting of Shareholders
News Preview
CALGARY, AB, Dec. 12, 2025 /PRNewswire/ - Decibel Cannabis Company Inc. (the "Company" or "Decibel") (TSXV: DB) (OTCQB: DBCCF), a market leader in premium cannabis and extract manufactured products, is pleased to announce that the results of its annual and special meeting of shareholders held on December 11, 2025 (the "Meeting")....
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
NTRA
LISTED
NASDAQ
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study, which is a multicenter, phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-)...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is e...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
News Preview
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
ATX
LISTED
ASX
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
News Preview
HIGHLIGHTS...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
News Preview
Final Decision from European Commission Expected in Q1 2026...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
